{"entity":{"id":"nct03960840","kind":"trial","name":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","aka":[],"tldr":"A phase 1/2 trial of Ibrutinib in diffuse large b-cell lymphoma, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL is a phase 1/2 interventional study registered as NCT03960840 by Novartis Pharmaceuticals, with 217 participants enrolled, started 2019-06-26 and due to reach its primary completion in 2027-06-30. Interventions recorded: Rapcabtagene autoleucel single agent, Ibrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03960840","url":"https://clinicaltrials.gov/study/NCT03960840"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["ibrutinib"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03960840","phase":"1/2","setting":"Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","sponsor":"Novartis Pharmaceuticals","enrolled":217,"outcomes":[]},"route":"/trials/nct03960840/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}